{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:35:46Z","timestamp":1791027346494,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s00213-010-2124-0","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T06:11:08Z","timestamp":1292911868000},"page":"149-163","source":"Crossref","is-referenced-by-count":48,"title":["AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents"],"prefix":"10.1007","volume":"215","author":[{"given":"Mark D.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Rogacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Featherstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaw","family":"Senyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odessa","family":"Giardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Borowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Stemmelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pichat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Segev","family":"Barak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"De Levie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Griebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Varty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/2271151b0","volume":"227","author":"EL Abel","year":"1970","unstructured":"Abel EL (1970) Marijuana and memory. Nature 227:1151\u20131152","journal-title":"Nature"},{"key":"2124_CR2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0091270008317591","volume":"48","author":"C Addy","year":"2008","unstructured":"Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depr\u00e9 M, Knops A, Gottesdiener K, Stoch A, Wagner J (2008) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol 48:734\u2013744","journal-title":"J Clin Pharmacol"},{"key":"2124_CR3","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62:22\u201331","journal-title":"J Clin Psychiatry"},{"key":"2124_CR4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0306-4522(98)00675-7","volume":"91","author":"R Alonso","year":"1999","unstructured":"Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, Soubri\u00e9 P (1999) Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91:607\u2013620","journal-title":"Neuroscience"},{"key":"2124_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(95)00661-3","volume":"295","author":"JJ Anderson","year":"1996","unstructured":"Anderson JJ, Kask AM, Chase TN (1996) Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. Eur J Pharmacol 295:163\u2013168","journal-title":"Eur J Pharmacol"},{"key":"2124_CR6","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1152\/jn.2000.83.6.3287","volume":"83","author":"N Auclair","year":"2000","unstructured":"Auclair N, Otani S, Soubrie P, Crepel F (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses. J Neurophysiol 83:3287\u20133293","journal-title":"J Neurophysiol"},{"key":"2124_CR7","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/sj.npp.1301344","volume":"32","author":"M Ballmaier","year":"2007","unstructured":"Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, Spano P (2007) Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32:2098\u20132107","journal-title":"Neuropsychopharmacology"},{"key":"2124_CR8","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/npp.2008.232","volume":"34","author":"S Barak","year":"2009","unstructured":"Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I (2009) Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in Pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 34:1753\u20131763","journal-title":"Neuropsychopharmacology"},{"key":"2124_CR9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0028-3908(99)00041-6","volume":"38","author":"MD Black","year":"1999","unstructured":"Black MD, Selk DE, Hitchcock JM, Wettstein JG, Sorensen SM (1999) On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology 38:1299\u20131306","journal-title":"Neuropharmacology"},{"key":"2124_CR10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0028-3908(01)00180-0","volume":"42","author":"MD Black","year":"2002","unstructured":"Black MD, Simmonds J, Senyah Y, Wettstein JG (2002) Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology 42:414\u2013420","journal-title":"Neuropharmacology"},{"key":"2124_CR11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00213-008-1289-2","volume":"202","author":"MD Black","year":"2009","unstructured":"Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202:385\u2013396","journal-title":"Psychopharmacology"},{"key":"2124_CR12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/archpsyc.1993.01820150074008","volume":"50","author":"FE Bloom","year":"1993","unstructured":"Bloom FE (1993) Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 50:224\u2013227","journal-title":"Arch Gen Psychiatry"},{"key":"2124_CR13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/schbul\/19.2.431","volume":"19","author":"B Bogerts","year":"1993","unstructured":"Bogerts B (1993) Recent advances in the neuropathology of schizophrenia. Schizophr Bull 19:431\u2013445","journal-title":"Schizophr Bull"},{"key":"2124_CR14","first-page":"S116","volume":"30","author":"B Borowsky","year":"2005","unstructured":"Borowsky B, Stevens R, Black M, Senyah Y, Rogacki N, Giardino O, Piot-Grosjean O, Pratt J, Lenox R (2005) AVE1625, a cannabinoid CB1 antagonist, as a co-treatment for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in animal models. Neuropsychopharmacology 30:S116","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 10","key":"2124_CR15","first-page":"55","volume":"58","author":"DE Casey","year":"1997","unstructured":"Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10):55\u201362","journal-title":"J Clin Psychiatry"},{"key":"2124_CR16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706\u20131713","journal-title":"Lancet"},{"key":"2124_CR17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0165-0173(00)00018-7","volume":"32","author":"A Contestabile","year":"2000","unstructured":"Contestabile A (2000) Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev 32:476\u2013509","journal-title":"Brain Res Brain Res Rev"},{"key":"2124_CR18","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1523\/JNEUROSCI.3936-06.2007","volume":"27","author":"AG Corbill\u00e9","year":"2007","unstructured":"Corbill\u00e9 AG, Valjent E, Marsicano G, Ledent C, Lutz B, Herv\u00e9 D, Girault JA (2007) Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 27:6937\u20136947","journal-title":"J Neurosci"},{"key":"2124_CR19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"DC D\u2019Souza","year":"2004","unstructured":"D\u2019Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558\u20131572","journal-title":"Neuropsychopharmacology"},{"key":"2124_CR20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D\u2019Souza","year":"2005","unstructured":"D\u2019Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594\u2013608","journal-title":"Biol Psychiatry"},{"key":"2124_CR21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","volume":"103","author":"B Dean","year":"2001","unstructured":"Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9\u201315","journal-title":"Neuroscience"},{"key":"2124_CR22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","volume":"8","author":"V Marzo Di","year":"2005","unstructured":"Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585\u2013589","journal-title":"Nat Neurosci"},{"key":"2124_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","volume":"31","author":"A Ennaceur","year":"1988","unstructured":"Ennaceur A, Delacour J (1988) A new one trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31:47\u201359","journal-title":"Behav Brain Res"},{"key":"2124_CR24","unstructured":"Featherstone RE, Potestio L, Bergis OE, Varty GB, Griebel G, Black MD (2009) SAR130479A, a novel selective \u03b17 nicotinic receptor partial agonist, for the treatment of symptoms of schizophrenia. III. Auditory evoked potentials (AEP) as a potential biomarker. Soc Neurosci Abs: 646.1."},{"key":"2124_CR25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0091-3057(99)00106-9","volume":"64","author":"F Ferrari","year":"1999","unstructured":"Ferrari F, Ottani A, Vivoli R, Giuliani D (1999) Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. Pharmacol Biochem Behav 64:555\u2013561","journal-title":"Pharmacol Biochem Behav"},{"key":"2124_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00213-002-1311-z","volume":"166","author":"I Gaisler-Salomon","year":"2003","unstructured":"Gaisler-Salomon I, Weiner I (2003) Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 166:333\u2013342","journal-title":"Psychopharmacology"},{"key":"2124_CR27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00213-007-0960-3","volume":"196","author":"I Gaisler-Salomon","year":"2008","unstructured":"Gaisler-Salomon I, Diamant L, Rubin C, Weiner I (2008) Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology 196:255\u2013267","journal-title":"Psychopharmacology"},{"key":"2124_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/336385a0","volume":"336","author":"J Garthwaite","year":"1988","unstructured":"Garthwaite J, Charles SL, Chess-Williams R (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336:385\u2013388","journal-title":"Nature"},{"key":"2124_CR29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.biopsych.2007.12.005","volume":"63","author":"M Haj\u00f3s","year":"2008","unstructured":"Haj\u00f3s M, Hoffmann WE, Kocsis B (2008) Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 63:1075\u20131083","journal-title":"Biol Psychiatry"},{"key":"2124_CR30","doi-asserted-by":"crossref","first-page":"E826","DOI":"10.1152\/ajpendo.00264.2007","volume":"293","author":"AW Herling","year":"2007","unstructured":"Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, M\u00fcller G, Schmoll D, Kramer W (2007) CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 293:E826\u2013832","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2124_CR31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0166-2236(00)01745-8","volume":"24","author":"JP Kiss","year":"2001","unstructured":"Kiss JP, Vizi ES (2001) Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci 24:211\u2013215","journal-title":"Trends Neurosci"},{"key":"2124_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0014-2999(00)00615-4","volume":"404","author":"AH Lichtman","year":"2000","unstructured":"Lichtman AH (2000) SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol 404:175\u2013179","journal-title":"Eur J Pharmacol"},{"key":"2124_CR33","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/oby.2010.17","volume":"18","author":"M Liebig","year":"2010","unstructured":"Liebig M, Gossel M, Pratt J, Black M, Haschke G, Elvert R, Juretschke HP, Neumann-Haefelin C, Kramer W, Herling AW (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity 18:1952\u20131958","journal-title":"Obesity"},{"key":"2124_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/schbul\/sbi005","volume":"31","author":"RE Lubow","year":"2005","unstructured":"Lubow RE (2005) Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull 31:139\u2013153","journal-title":"Schizophr Bull"},{"key":"2124_CR35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pbb.2005.02.017","volume":"81","author":"T Lundqvist","year":"2005","unstructured":"Lundqvist T (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81:319\u2013330","journal-title":"Pharmacol Biochem Behav"},{"key":"2124_CR36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","volume":"159","author":"M Martin","year":"2002","unstructured":"Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159:379\u2013387","journal-title":"Psychopharmacology"},{"key":"2124_CR37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00213-002-1240-x","volume":"165","author":"RS Martin","year":"2003","unstructured":"Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA (2003) Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology 165:128\u2013135","journal-title":"Psychopharmacology"},{"key":"2124_CR38","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1523\/JNEUROSCI.19-16-06795.1999","volume":"19","author":"DL Misner","year":"1999","unstructured":"Misner DL, Sullivan JM (1999) Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 19:6795\u20136805","journal-title":"J Neurosci"},{"key":"2124_CR39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0376-6357(89)80010-5","volume":"8","author":"R Misslin","year":"1989","unstructured":"Misslin R, Belzung C, Vogel E (1989) Behavioural validation of a light\/dark choice procedure for testing anti-anxiety agents. Behav Process 8:119\u2013132","journal-title":"Behav Process"},{"key":"2124_CR40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","volume":"23","author":"FA Moreira","year":"2009","unstructured":"Moreira FA, Grieb M, Lutz B (2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133\u2013144","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2124_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neulet.2005.12.026","volume":"397","author":"FA Pamplona","year":"2006","unstructured":"Pamplona FA, Takahashi RN (2006) WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci Lett 397:88\u201392","journal-title":"Neurosci Lett"},{"issue":"Suppl 1","key":"2124_CR42","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","volume":"147","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG (2006) Cannabinoid pharmacology: the first 66\u00a0years. Br J Pharmacol 147(Suppl 1):S163\u2013S171","journal-title":"Br J Pharmacol"},{"key":"2124_CR43","unstructured":"Pierce RC, Kalivas PW (2007) Locomotor behavior. Curr Protoc Neurosci Chapter 8:Unit 8.1."},{"key":"2124_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.0953-816x.2001.01612.x","volume":"14","author":"M Pistis","year":"2001","unstructured":"Pistis M, Porcu G, Melis M, Diana M, Gessa GL (2001) Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 14:96\u2013102","journal-title":"Eur J Neurosci"},{"key":"2124_CR45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s002130050987","volume":"144","author":"M Poncelet","year":"1999","unstructured":"Poncelet M, Barnouin MC, Breli\u00e8re JC, Le Fur G, Soubri\u00e9 P (1999) Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144:144\u2013150","journal-title":"Psychopharmacology"},{"key":"2124_CR46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0163-7258(01)00130-9","volume":"90","author":"AC Porter","year":"2001","unstructured":"Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45\u201360","journal-title":"Pharmacol Ther"},{"key":"2124_CR47","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0024-3205(96)00085-9","volume":"58","author":"M Rinaldi-Carmona","year":"1996","unstructured":"Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Breli\u00e8re JC, Soubri\u00e9 P, Le Fur G (1996) Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 58:1239\u20131247","journal-title":"Life Sci"},{"key":"2124_CR48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/15622970801908047","volume":"11","author":"P Roser","year":"2010","unstructured":"Roser P, Vollenweider FX, Kawohl W (2010) Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry 11:208\u2013219","journal-title":"World J Biol Psychiatry"},{"key":"2124_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0896-6273(94)90347-6","volume":"13","author":"AJ Roskams","year":"1994","unstructured":"Roskams AJ, Bredt DS, Dawson TM, Ronnett GV (1994) Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons. Neuron 13:289\u2013299","journal-title":"Neuron"},{"key":"2124_CR50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.niox.2004.04.001","volume":"10","author":"E S\u00e1nchez-Islas","year":"2004","unstructured":"S\u00e1nchez-Islas E, Le\u00f3n-Olea M (2004) Nitric oxide synthase inhibition during synaptic maturation decreases synapsin I immunoreactivity in rat brain. Nitric Oxide 10:141\u2013149","journal-title":"Nitric Oxide"},{"key":"2124_CR51","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008877-200312000-00001","volume":"14","author":"LP Shearman","year":"2003","unstructured":"Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, Rocha BA (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 14:573\u2013582","journal-title":"Behav Pharmacol"},{"key":"2124_CR52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/mol.55.1.8","volume":"55","author":"M Shen","year":"1999","unstructured":"Shen M, Thayser SA (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8\u201313","journal-title":"Mol Pharmacol"},{"key":"2124_CR53","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1523\/JNEUROSCI.16-14-04322.1996","volume":"16","author":"M Shen","year":"1996","unstructured":"Shen M, Piser TM, Seybold VS, Thayer SA (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322\u20134334","journal-title":"J Neurosci"},{"key":"2124_CR54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neulet.2005.01.049","volume":"380","author":"RN Takahashi","year":"2005","unstructured":"Takahashi RN, Pamplona FA, Fernandes MS (2005) The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270\u2013275","journal-title":"Neurosci Lett"},{"key":"2124_CR55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02246352","volume":"126","author":"JP Terranova","year":"1996","unstructured":"Terranova JP, Storme JJ, Lafon N, P\u00e9\u0155io A, Rinaldi-Carmona M, Le Fur G, Soubri\u00e9 P (1996) Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126:165\u2013172","journal-title":"Psychopharmacology"},{"key":"2124_CR56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.pbb.2008.01.010","volume":"89","author":"G Thiemann","year":"2008","unstructured":"Thiemann G, Di Marzo V, Molleman A, Hasen\u00f6hrl RU (2008) The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacol Biochem Behav 89:384\u2013391","journal-title":"Pharmacol Biochem Behav"},{"key":"2124_CR57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1254\/jphs.FMJ04003X4","volume":"96","author":"H Ujike","year":"2004","unstructured":"Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96:376\u2013381","journal-title":"J Pharmacol Sci"},{"key":"2124_CR58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2003.08.101","volume":"480","author":"M Stelt Van der","year":"2003","unstructured":"Van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133\u2013150","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 3","key":"2124_CR59","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.euroneuro.2006.06.005","volume":"16","author":"LF Gaal Van","year":"2006","unstructured":"Van Gaal LF (2006) Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 16(Suppl 3):S142\u2013148","journal-title":"Eur Neuropsychopharmacol"},{"key":"2124_CR60","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","volume":"44","author":"DR Weinberger","year":"1987","unstructured":"Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660\u2013669","journal-title":"Arch Gen Psychiatry"},{"key":"2124_CR61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0920-9964(95)00013-C","volume":"16","author":"DR Weinberger","year":"1995","unstructured":"Weinberger DR, Lipska BK (1995) Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16:87\u2013110","journal-title":"Schizophr Res"},{"key":"2124_CR62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-002-1313-x","volume":"169","author":"I Weiner","year":"2003","unstructured":"Weiner I (2003) The \u201ctwo-headed\u201d latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169:257\u2013297","journal-title":"Psychopharmacology"},{"key":"2124_CR63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbr.2009.05.004","volume":"204","author":"I Weiner","year":"2009","unstructured":"Weiner I, Arad M (2009) Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res 204:369\u2013386","journal-title":"Behav Brain Res"},{"key":"2124_CR64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/089771503767168528","volume":"20","author":"W Wu","year":"2003","unstructured":"Wu W, Li L, Yick LW, Chai H, Yang Y, Prevette DM, Oppenheim RW (2003) GDNF and BDNF alter the expression of neuronal NOS, c-Jun, and p75 and prevent motoneurons death following spinal root avulsion in adult rats. J Neurotrauma 20:603\u201312","journal-title":"J Neurotrauma"},{"key":"2124_CR65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","volume":"28","author":"K Zavitsanou","year":"2004","unstructured":"Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355\u2013360","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2124-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-010-2124-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2124-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:23:11Z","timestamp":1637022191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-010-2124-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1007\/s00213-010-2124-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}